- Home
- NNY vs ELDN Comparison
NNY vs ELDN Comparison
Compare NNY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ELDN
- Stock Information
- Founded
- NNY 1987
- ELDN 2004
- Country
- NNY United States
- ELDN United States
- Employees
- NNY N/A
- ELDN N/A
- Industry
- NNY Investment Managers
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- ELDN Health Care
- Exchange
- NNY Nasdaq
- ELDN Nasdaq
- Market Cap
- NNY 163.0M
- ELDN 140.3M
- IPO Year
- NNY N/A
- ELDN N/A
- Fundamental
- Price
- NNY $8.26
- ELDN $4.00
- Analyst Decision
- NNY
- ELDN Strong Buy
- Analyst Count
- NNY 0
- ELDN 1
- Target Price
- NNY N/A
- ELDN $16.00
- AVG Volume (30 Days)
- NNY 50.9K
- ELDN 985.1K
- Earning Date
- NNY 01-01-0001
- ELDN 11-12-2024
- Dividend Yield
- NNY 4.04%
- ELDN N/A
- EPS Growth
- NNY N/A
- ELDN N/A
- EPS
- NNY N/A
- ELDN N/A
- Revenue
- NNY N/A
- ELDN N/A
- Revenue This Year
- NNY N/A
- ELDN N/A
- Revenue Next Year
- NNY N/A
- ELDN N/A
- P/E Ratio
- NNY N/A
- ELDN N/A
- Revenue Growth
- NNY N/A
- ELDN N/A
- 52 Week Low
- NNY $7.58
- ELDN $1.11
- 52 Week High
- NNY $8.87
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- NNY 27.40
- ELDN 49.97
- Support Level
- NNY $8.33
- ELDN $4.74
- Resistance Level
- NNY $8.45
- ELDN $5.40
- Average True Range (ATR)
- NNY 0.08
- ELDN 0.53
- MACD
- NNY -0.01
- ELDN -0.11
- Stochastic Oscillator
- NNY 3.70
- ELDN 24.51
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.